Can you use BPC-157 after surgery?

Why Timing Matters After Surgery

Post-surgical healing happens in distinct phases, and BPC-157's effects don't align with all of them equally:

• Hemostasis and clot formation (days 0–3): initial fibrin clot is load-bearing and important. Most practitioners avoid BPC-157 here, concerned that strong angiogenic signaling could destabilize the clot.
• Inflammatory phase (days 3–7): controlled inflammation is part of proper healing. Again, BPC-157 is usually deferred.
• Proliferative phase (days 7–21): fibroblasts migrate, new blood vessels form, new tissue deposits. This is where BPC-157's mechanisms fit best.
• Remodeling phase (weeks 3–12+): tissue matures and aligns. BPC-157 remains useful.

Practical consequence: most post-surgical BPC-157 protocols start 2 weeks after surgery and run into the proliferative and remodeling windows.

Surgeries Where BPC-157 Is Most Commonly Used

• Rotator cuff repair
• ACL and meniscus reconstruction
• Achilles tendon repair
• Abdominal wall and hernia repair
• Gastric and bowel surgery (intestinal anastomosis healing — strong preclinical evidence)
• Tommy John (UCL reconstruction) in baseball players

Surgeries Where You Should Be More Cautious

• Cancer-related surgery — angiogenic effects are a concern in any patient with active or recent malignancy
• Ophthalmic surgery — not a typical peptide indication; defer to ophthalmology
• Neurosurgery — limited data; defer to neurosurgical team
• Elective cosmetic surgery — risk/reward balance is different than functional surgery

Standard Post-Op Protocol

• Start: Day 14 post-op, after reviewing with surgeon
• Dose: 250–500 mcg subcutaneously daily
• Cycle: 6–8 weeks
• Delivery: Subcutaneous abdominal injection; avoid injection sites over or near surgical incisions

Why Surgeon Coordination Is Essential

Post-surgical BPC-157 use sits at the intersection of:

• Surgical outcomes and liability
• Off-label regulatory considerations
• Potential interactions with prescribed post-op medications (blood thinners, antibiotics, pain medications)
• Timing relative to follow-up imaging and structural evaluation

Many surgeons have no objection to BPC-157 and some actively recommend it. Others will not approve it. Using BPC-157 without disclosing it to your surgical team is a bad idea — it compromises their ability to interpret your recovery and to safely manage complications if they arise.

Patient-Reported Post-Op Experience

Common reports from patients who use BPC-157 post-operatively, alongside standard rehab:

• Reduced soft-tissue swelling
• Faster return of range of motion milestones
• Less post-rehab session soreness
• Subjective sense of better recovery pace compared to prior surgeries without it

These reports are meaningful but not controlled — expectation effects, confounders, and selection bias all play a role. Formal randomized post-operative BPC-157 trials are lacking.

Post-Op Red Flags

Stop BPC-157 and contact your surgical team immediately for any of:

• New unexplained swelling or warmth at the surgical site
• Increased drainage from the incision
• Fever
• Severe or worsening pain rather than improving pain
• Any bleeding beyond baseline expected amount

See the main BPC-157 guide. Related: rotator cuff use, Wolverine Stack dosage.